Edoxaban versus warfarin in patients with atrial fibrillation in relation to stroke risk. A subanalysis of the ENGAGE AF-TIMI 48 study

Back

ESC Premium Access

Edoxaban versus warfarin in patients with atrial fibrillation in relation to stroke risk. A subanalysis of the ENGAGE AF-TIMI 48 study

Session: Anticoagulation in atrial fibrillation

Topic: Atrial fibrillation (AF)

Speaker: Professor J. De Groot (Amsterdam, NL)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Joris R De Groot

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))

16 presentations

3 followers

9 more presentations in this session

Atrial fibrillation and venous thromboembolism. a Swedish nationwide registry study on 1358274 individuals.

Speaker: Assistant Professor B. Hornestam (Gothenburg, SE)

Higher risk of dementia without oral anticoagulation in atrial fibrillation

Speaker: Associate Professor L. Friberg (Stockholm, SE)

Anticoagulant use and associated outcomes in patients with atrial fibrillation and advanced kidney disease

Speaker: Doctor P. Noseworthy (Rochester, US)

Age and gender differences in stroke and bleeding risks in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants

Speaker: Doctor P. Noseworthy (Rochester, US)

Similar long-term risk of thromboembolic events in postoperative atrial fibrillation following coronary artery bypass grafting and non-valvular atrial fibrillation: need for anticoagulation?

Speaker: Mr J. Butt (Copenhagen, DK)

Access the full session

Anticoagulation in atrial fibrillation

Speakers: Professor J. De Groot, Assistant Professor B. Hornestam, Associate Professor L. Friberg, Doctor P. Noseworthy, Doctor P. Noseworthy...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources